←Back to Expert Scholars
Translational Medicine / 转化医学Liposarcoma, CDK4 Inhibitors
Mark Dickson
MD
🏢Memorial Sloan Kettering Cancer Center🌐USA
Sarcoma Medical Oncologist
55
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Mark Dickson led pivotal trials of palbociclib in CDK4 amplified dedifferentiated liposarcoma that established proof of concept for CDK4 targeting in sarcoma. His work has shaped precision oncology in liposarcoma. He runs trials of novel agents in well differentiated and dedifferentiated liposarcoma.
Share:
🧪Research Fields 研究领域
dedifferentiated liposarcoma
CDK4 inhibitor
palbociclib
MDM2
sarcoma trials
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Mark Dickson 的研究动态
Follow Mark Dickson's research updates
留下邮箱，当我们发布与 Mark Dickson（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment